Nabi Biopharmaceuticals realized $10.5 million in revenue in its fiscal fourth quarter after collecting development payments from GlaxoSmithKline PLC for its PentaStaph drug. (NABI)
Nabi Biopharmaceuticals logs revenue from Glaxo sale
Wed, 03/10/2010 - 6:51pm


Post new comment